## REGN: Regeneron Pharmaceuticals, Inc. - XLV: Healthcare

### Executive Summary

STRENGTH thesis confirmed: MRS_20 at 4.1% in lower entry zone (4.0-10.0%), top 9% cross-sectional ranking. Short-term MRS_5 (0.2%) confirms momentum alignment. Strong momentum (+1.4% 5-day acceleration). Outperforming sector by 3.5%. Caution: declining volume (48% of avg).

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($747.53)
- **If Wrong:** Exit if MRS_20 drops below entry zone or breaks stop
- **Invalidation:** MRS_20 exits entry zone or MRS_5 turns negative

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 6, Bearish: 0)

**1. Morgan Stanley Sees Policy Risks Receding for Regeneron (REGN)**
- Source: Finviz | 20251227T040811 | Bullish | Relevance: 100%
- Morgan Stanley analyst Terence Flynn raised the price target for Regeneron Pharmaceuticals (REGN) to $768, maintaining an Equal Weight rating, believing policy concerns that impacted biopharma will lessen in 2026. The company also recently received marketing and manufacturing authorization in Japan for Dupixent (dupilumab) to treat bronchial asthma in children, expanding its earlier approval. Regeneron and Sanofi continue to explore dupilumab's potential in various other conditions with ongoing Phase 3 trials.

**2. Vontobel Holding Ltd. Has $5.83 Million Stock Position in Regeneron Pharmaceuticals, Inc. $REGN**
- Source: MarketBeat | 20251226T130800 | Somewhat-Bullish | Relevance: 100%
- Vontobel Holding Ltd. significantly increased its stake in Regeneron Pharmaceuticals (NASDAQ: REGN) by 38.1% to 10,363 shares, valued at $5.83 million, in the third quarter. This move follows Regeneron's strong Q3 earnings, where it surpassed analyst estimates with EPS of $11.83 and revenue of $3.75 billion. The biopharmaceutical company currently holds a consensus "Moderate Buy" rating from analysts with a price target of $779.45, while institutional investors own 83.31% of the stock.

**3. TB Alternative Assets Ltd. Increases Position in Regeneron Pharmaceuticals, Inc. $REGN**
- Source: MarketBeat | 20251228T114850 | Bullish | Relevance: 100%
- TB Alternative Assets Ltd. significantly increased its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 174.0% in Q3, now holding 8,652 shares valued at $4.865 million. This makes Regeneron its 27th-largest position. The company also reported strong quarterly earnings, topping analyst estimates, and announced a quarterly dividend.

**4. Bellecapital International Ltd. Buys 2,276 Shares of Regeneron Pharmaceuticals, Inc. $REGN**
- Source: MarketBeat | 20251228T080841 | Bullish | Relevance: 100%
- Bellecapital International Ltd. increased its holdings in Regeneron Pharmaceuticals (NASDAQ:REGN) by 8.9%, purchasing 2,276 shares to own a total of 27,779 shares valued at $15.62 million. This move makes Regeneron its 16th largest holding, comprising about 2.5% of its portfolio. Other institutions like Dodge & Cox and Norges Bank also significantly increased their stakes, bringing institutional ownership to approximately 83.3%.

**5. Cwm LLC Has $30.03 Million Stake in Regeneron Pharmaceuticals, Inc. $REGN**
- Source: MarketBeat | 20251227T091726 | Bullish | Relevance: 100%
- Cwm LLC recently increased its stake in Regeneron Pharmaceuticals (NASDAQ:REGN) by 50.4%, bringing its total holding to 53,406 shares valued at approximately $30.03 million. Other institutional investors also adjusted their positions in the biopharmaceutical company, which recorded strong Q3 earnings, surpassing analyst expectations for both EPS and revenue. Regeneron also announced a quarterly dividend and currently holds a "Moderate Buy" consensus rating from analysts with an average price target of $779.45.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 4, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-12 | Morgan Stanley | $768 | $767 | +0% |
| 2025-12-10 | Wells Fargo | $745 | $700 | +6% |
| 2025-12-04 | Canaccord Genui | $1057 | $850 | +24% |
| 2025-12-04 | BMO Capital | $850 | $725 | +17% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-12 | Morgan Stanley | main | Equal-Weight |
| 2025-12-10 | Wells Fargo | main | Equal-Weight |
| 2025-12-04 | Canaccord Genui | main | Buy |
| 2025-12-04 | BMO Capital | main | Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 9 ($97.67M) |
| Sells | 15 ($32.83M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 44.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 8.8% (-4.0%)
- Blackrock Inc.: 8.6% (-4.7%)
- JPMORGAN CHASE & CO: 7.9% (+106.7%)
- State Street Corpora: 4.5% (-2.9%)
- Dodge & Cox Inc.: 4.4% (+18.9%)

### Key Risks

1. Volume divergence: price rising (+1.4% MRS) on declining volume (48% of avg) suggests distribution.
2. Heavy insider selling: $33M sold (15 transactions in 90 days).
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Analyst target momentum: 4 raises (avg +12%) could attract flows.
- Momentum building: MRS_20 improving +1.4% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 1.55 elevated, pricing in significant growth expectations. Quality metrics strong (margin 32%). Balance sheet: strong liquidity (4.1x), low leverage (D/E 0.30), $1.4B free cash flow. Analyst sentiment positive (4 raises, avg +12%). Insider buying signal ($97.7M), management confidence. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $83.2B |
| Beta | 0.37 |
| 52W Range | $476.49 - $792.77 |
| Short Interest | 2.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.55 |
| Forward P/E | 20.5 |
| Current P/E | 18.2 |
| YoY Growth | -11.2% |
| EPS Direction | RISING |

### Technicals

MRS_20 strengthening from 2.7% to 4.1% (+1.4% in 5 days), confirming momentum buildup. Currently in lower STRENGTH zone (4.0-10.0%), cross-sectional ranking at 90th percentile. MRS_5 at 0.2% confirms short-term momentum alignment. AM_20 at 5.0% shows strong absolute momentum above own 20MA. Outperforming sector by 3.5pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (1.61), confirming momentum. Volume at 48% of 20MA suggests lack of conviction. OFD pattern: +DBL (Indecision).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 4.06% (CS: 91) | Strong |
| RSI_14 | 67.5 | Neutral |
| MACD Histogram | 1.61 | Bullish |
| vs SMA20 | 1.050x | Above |
| vs SMA50 | 1.129x | Above |
| vs SMA200 | 1.303x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $784.97
- **Stop Loss:** $747.53 (4.8% risk)
- **Target:** $841.13 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 35
- **Position Value:** $27,473.95
- **Portfolio %:** 27.47%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with selective risk appetite amid holiday trading. VIX at extreme lows (13.6) signals complacency while positive yield curve (+59bps) and stable economic data support continuation. Focus on quality names with AI/infrastructure exposure while monitoring January volatility reset.*

### Earnings

**Next:** 2026-02-03 (Est: $10.77)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $9.64 | $11.83 | +22.7% |
| 2025Q2 | $8.44 | $12.89 | +52.7% |
| 2025Q1 | $8.48 | $8.22 | -3.0% |
| 2024Q4 | $11.19 | $12.07 | +7.8% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_20*